Search
Neurosense Therapeutics Ltd
NRSNAdd to Watchlist
0.723USD
+0.003+0.42%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
23.54MMarket Cap
LossP/E TTM
More Details of Neurosense Therapeutics Ltd Company
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Neurosense Therapeutics Ltd Info
Ticker SymbolNRSN
Company nameNeurosense Therapeutics Ltd
IPO dateDec 09, 2021
CEOBen-Noon (Alon)
Number of employees15
Security typeOrdinary Share
Fiscal year-endDec 09
Address11 Hamenofim St.
CityHERZLIYA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code4672562
Phone97297996183
Websitehttps://www.neurosense-tx.com/
Ticker SymbolNRSN
IPO dateDec 09, 2021
CEOBen-Noon (Alon)
Company Executives of Neurosense Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Neurosense Therapeutics Ltd?
The top five shareholders of Neurosense Therapeutics Ltd are: Mr. Alon Ben-Noon
How many institutions hold shares of Neurosense Therapeutics Ltd (NRSN)?
As of 2026Q1, 33 institutions hold shares of Neurosense Therapeutics Ltd, with a combined market value of approximately 367.79K, accounting for 1.04% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2009158.00.